Nonalcoholic steatohepatitis (NASH) is considered the progressive form of nonalcoholic fatty
liver disease (NAFLD) and is characterized by liver steatosis, inflammation, hepatocellular …

The dietary recommendation encourages reducing saturated fatty acids (SFA) in diet and
replacing them with polyunsaturated fatty acids (PUFAs) n–3 (omega–3) and n–6 (omega …

The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the
paucity of human-relevant models for target discovery and compound screening. Here we …

Lipid and immune pathways are crucial in the pathophysiology of metabolic and
cardiovascular disease. Arachidonic acid (AA) and its derivatives link nutrient metabolism to …

The prevalence of nonalcoholic steatohepatitis (NASH) is increasing worldwide, yet there
are no effective treatments. A decade has passed since the initial lipidomics analyses of liver …

Inflammation is associated with the development of diseases characterized by altered
nutrient metabolism. Although an acute inflammatory response is host-protective and …

Non-alcoholic fatty liver disease (NAFLD) represents the most common form of chronic liver
disease worldwide (about 25% of the general population) and 3–5% of patients develop non …

In nonalcoholic fatty liver disease, hepatic gene expression and fatty acid (FA) composition
have been reported independently, but a comprehensive gene expression profiling in …

Obesity and its associated disorders, such as insulin resistance, dyslipidemia, metabolic
inflammation, dysbiosis, and non-alcoholic hepatic steatosis, are involved in several …

Nonalcoholic steatohepatitis (NASH) is a condition which can progress to cirrhosis and
hepatocellular carcinoma. Markers for NASH diagnosis are still lacking. We performed a …